WaveMan
WaveMan · Company
EW · Edwards Lifesciences Corp
> Search tickers & screens ⌘K
LIVE
← All companies

EW Edwards Lifesciences (EW) Insider Trading, Ownership & Congress Trades

Medical Devices · Orthopedic, prosthetic & surgical appliances & supplies · CIK 0001099800
Quote by TradingView
Form 144 · 7
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
646
13F, latest reported quarter
Conversions, 180 days
15
Codes C/M, not in net · $4.2M priced

What the filings say about EW

Insiders, 180 days
-$11.4M net sold
7 sellers · 8% of sales under a 10b5-1 plan
Congress, 1 year
0 bought · 1 sold
Latest: sale, 2025-11-19
Planned sales (Form 144), 90 days
$8.1M
7 notices

Edwards Lifesciences insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Edwards Lifesciences Corp insiders sold a net $11.4M of stock across 385 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.

Insider
Filed
Shares
Value
Since filing
Lippis Daniel J.
CVP, TAVR
SELL
2026-10-08 SEC
619
$53.0K
+4.5%
Context
  • 25 earlier Form 4 trades (code P or S) here by this insider (25 sales), the last on Sep 11, 2026.
  • The trade is 1.5% of the 40,033 shares held after it.
  • No other insider sold within 30 days.
  • 646 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CVP, TAVR Lippis Daniel J. sold about $53.0K of EW under a 10b5-1 plan on Oct 8, 2026; 646 funds added in the latest 13F quarter.
Lippis Daniel J.
CVP, TAVR
SELL
2026-09-11 SEC
619
$54.2K
+4.2%
Context
  • 24 earlier Form 4 trades (code P or S) here by this insider (24 sales), the last on Aug 11, 2026.
  • The trade is 1.5% of the 40,033 shares held after it.
  • 4 other insiders sold within 30 days.
  • 646 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CVP, TAVR Lippis Daniel J. sold about $54.2K of EW under a 10b5-1 plan on Sep 11, 2026; 4 other insiders sold within 30 days and 646 funds added in the latest 13F quarter.
Dahl Andrew M.
SVP, Corporate Controller
SELL
2026-08-31 SEC
544
$49.5K
-1.8%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on May 29, 2026.
  • The trade is 3.7% of the 14,868 shares held after it.
  • 4 other insiders sold within 30 days.
  • 646 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SVP, Corporate Controller Dahl Andrew M. sold about $49.5K of EW on Aug 31, 2026; 4 other insiders sold within 30 days and 646 funds added in the latest 13F quarter.
Bruls Annette
CVP, EMEACLA
SELL
2026-08-28 SEC
2,644
$237.9K
-1.9%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 14.7% of the 17,984 shares held after it.
  • 4 other insiders sold within 30 days.
  • 646 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CVP, EMEACLA Bruls Annette sold about $237.9K of EW on Aug 28, 2026; 4 other insiders sold within 30 days and 646 funds added in the latest 13F quarter.
Markowitz Wayne
CVP, JAPAC
SELL
2026-08-26 SEC
1,240
$113.4K
-1.0%
Context
  • 6 earlier Form 4 trades (code P or S) here by this insider (6 sales), the last on Jul 30, 2026.
  • The trade is 6.1% of the 20,293 shares held after it.
  • 5 other insiders sold within 30 days.
  • 646 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CVP, JAPAC Markowitz Wayne sold about $113.4K of EW on Aug 26, 2026; 5 other insiders sold within 30 days and 646 funds added in the latest 13F quarter.
385 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 380 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$11.4M over 180 days
-$3.5M over 90 days
below 87% of Medical Devices
Congress
no House purchase disclosed in the last 12 months
Funds
646 funds bought in last quarter
more than 97% of Medical Devices
Revenue
+11.5% year over year
more than 53% of Medical Devices
Margin
17.7% net margin
more than 90% of Medical Devices
Buybacks
$575.1M repurchased, FY to 2026-06-30
more than 90% of Medical Devices
Short interest
1.7% of the float short (float per yahoo 2026-10-26) · 2.5 days to cover · settled 2026-09-30
below 68% of Medical Devices
The situation: each line is one rule over one dataset
5 trial completion dates slipped in the last 90 days.
What changed in the last 30 days
Oct 8CVP, TAVR Lippis Daniel J. sold $53.0K under a 10b5-1 plan (Oct 8)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.

Watch EW

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+15.9%12M
-1%+7%+15%+24%2025-102025-122026-022026-042026-062026-082026-10 2026-08-26 · Chopra Daveen sold $2.8M2026-05-12 · Zovighian Bernard J sold $2.8M2026-02-25 · BOBO DONALD E JR sold $2.0M2026-05-27 · BOBO DONALD E JR sold $2.0M2025-12-08 · Zovighian Bernard J sold $1.8M2026-02-12 · Zovighian Bernard J sold $1.5M2026-04-02 · BOBO DONALD E JR sold $1.4M2026-03-02 · BOBO DONALD E JR sold $974.4K2025-12-10 · BOBO DONALD E JR sold $950.6K2025-11-10 · Ullem Scott B. sold $832.4K2026-07-28 · Markowitz Wayne sold $819.0K2026-05-15 · BOBO DONALD E JR sold $818.1K2026-01-06 · BOBO DONALD E JR sold $748.7K2026-03-11 · Ullem Scott B. sold $673.2K2026-04-09 · Ullem Scott B. sold $664.2K2026-05-15 · BOBO DONALD E JR sold $654.6K2025-12-09 · Ullem Scott B. sold $650.4K2025-12-12 · BOBO DONALD E JR sold $494.1K2025-12-12 · BOBO DONALD E JR sold $459.7K2026-03-11 · Ullem Scott B. sold $430.7K2026-04-02 · BOBO DONALD E JR sold $376.8K2026-04-09 · Ullem Scott B. sold $376.4K2025-12-10 · Zovighian Bernard J sold $322.4K2025-11-10 · Ullem Scott B. sold $247.7K2026-07-27 · Zovighian Bernard J sold $245.1K2026-08-28 · Bruls Annette sold $237.9K2026-01-06 · BOBO DONALD E JR sold $222.7K2025-12-12 · STONE HEISZ LESLIE sold $218.1K2026-02-12 · Zovighian Bernard J sold $195.3K2025-12-11 · Chopra Daveen sold $168.8K2026-05-22 · Chopra Daveen sold $126.9K2026-08-26 · Markowitz Wayne sold $113.4K2026-08-26 · Chopra Daveen sold $105.9K2026-01-09 · Lippis Daniel J. sold $87.3K2026-03-11 · Lippis Daniel J. sold $87.0K2025-12-12 · Lippis Daniel J. sold $85.6K2026-05-04 · Lippis Daniel J. sold $85.6K2025-11-10 · Lippis Daniel J. sold $84.2K2026-05-01 · Lippis Daniel J. sold $83.0K2026-04-06 · Lippis Daniel J. sold $82.5K2026-05-12 · Zovighian Bernard J sold $66.2K2026-08-11 · Lippis Daniel J. sold $57.0K2026-08-31 · Dahl Andrew M. filed to sell $49.5K2026-08-28 · Bruls Annette filed to sell $237.9K2026-08-26 · Chopra Daveen filed to sell $2.9M2026-08-26 · Markowitz Wayne filed to sell $113.4K2026-08-11 · Lippis Daniel J. filed to sell $170.9K2026-07-30 · Markowitz Wayne filed to sell $12.6K2026-07-30 · Ullem Scott B. filed to sell $4.6M2026-07-28 · Markowitz Wayne filed to sell $819.0K2026-07-27 · Zovighian Bernard J filed to sell $245.1K
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns EW: institutional holders (13F)

13F holdings, latest reported quarter
BlackRock, Inc.
58,789,433 sh
$5.3B
VANGUARD CAPITAL MANAGEMENT LLC
37,615,952 sh
$3.4B
VANGUARD PORTFOLIO MANAGEMENT LLC
26,411,402 sh
$2.4B
STATE STREET CORP
26,321,940 sh
$2.4B
JPMORGAN CHASE & CO
22,783,175 sh
$2.1B

Congress trades in EW

STOCK Act disclosures, US House only, filed up to 45 days after the trade
Josh Gottheimer
Sold 2025-11-19 · disclosed 40 days later
$1,001 - $15,000
Jefferson Shreve
Sold 2025-05-12 · disclosed 41 days later
$50,001 - $100,000
Bruce Westerman
Sold 2025-04-21 · disclosed 21 days later
$1,001 - $15,000
Rob Bresnahan
Bought 2025-04-08 · disclosed 30 days later
$1,001 - $15,000
Jefferson Shreve
Bought 2025-04-07 · disclosed 31 days later
$15,001 - $50,000
All stocks members of Congress are buying · Every member's trades

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

EW planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
Dahl Andrew M.
Filed 2026-08-31
$49.5K
Bruls Annette
Filed 2026-08-28
$237.9K
Chopra Daveen
Filed 2026-08-26
$2.9M
Markowitz Wayne
Filed 2026-08-26
$113.4K
Lippis Daniel J.
Filed 2026-08-11
$170.9K

EW mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
iShares U.S. Medical Devices ETF
$143.7M position · as of 2026-06-30
4.8%
iShares Health Innovation Active ETF
$492.8K position · as of 2026-07-31
4.4%
Select Medical Technology and Devices Portfolio
$125.4M position · as of 2026-05-31
4.2%
Brown Advisory Global Leaders Fund
$73.5M position · as of 2026-06-30
3.3%
The Future Fund Long/Short ETF
$1.4M position · as of 2026-05-31
3.2%
Goldman Sachs Future Health Care Equity ETF
$600.0K position · as of 2026-05-31
3.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
85 registered trials, 46 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
85
Not applicable
46 active
What changed recently
TRIFORMIS RESILIA Real-world Study Assessing Safety and Performance (TRIBLAZE Study)
2026-10-22 · Not Yet Recruiting → Recruiting
,
Autus Valve Continued Access Study (CAS)
2026-10-21 · Recruiting → Active Not Recruiting
Not applicable
The ENCIRCLE Trial
2026-10-07 · Completion moved 2027-02-28 → 2027-10-10
Not applicable
The ENCIRCLE Trial
2026-10-07 · Recruiting → Active Not Recruiting
Not applicable
Early Feasibility Study - Edwards APTURE Transcatheter Shunt System
2026-10-03 · Completion moved 2023-12-15 → 2027-04
Not applicable
Early Feasibility Study - Edwards APTURE Transcatheter Shunt System
2026-10-03 · Active Not Recruiting → Recruiting
Not applicable
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Corporate PAC
The company's PAC: committee totals only, never individual donors (FEC).
Edwards Lifesciences Political Action Committee (A.K.A. Edwards Pac)
Cycle 2026 · $297K spent
$273.6K
Federal Election Commission, matched by the PAC's connected organisation
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $11.4M sold by insiders over 180 days, 646 funds added last quarter, $8.1M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
PENBLFSMTDSIBNWRBYISRGTXGDXCMTMDXOMIRMDLUNG

EW financials

Revenue growth
+11.5%
XBRL, annual
Net margin
17.7%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$6.5B
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
+15.4%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
$1.4B
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
0.06x
long-term 2026-06-30 plus current 2018-12-31 (91 months older than the period end); equity 2026-06-30
Cash flow to debt
2.87x
TTM operating cash flow over long-term 2026-06-30 plus current 2018-12-31 (91 months older than the period end)
Return on equity
+9.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
+7.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
+12.4%
operating income after a 31.0% effective tax rate, over long-term 2026-06-30 plus current 2018-12-31 (91 months older than the period end) plus average of 2025-06-30 and 2026-06-30 minus cash
Return on capital employed
+11.9%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
51.19x
close 2026-10-23 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
Enterprise value
$49.0B
market value at close 2026-10-23 on 2026-07-31 shares, plus long-term 2026-06-30 plus current 2018-12-31 (91 months older than the period end), minus cash 2026-06-30
FCF yield
+2.8%
TTM free cash flow over market value at close 2026-10-23
PEG, trailing
n/a
trailing EPS growth -75%, PEG needs growth
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$6.1B$5.4B$6.0B$5.4B
Gross profit$4.7B$4.3B$4.0B$3.7B
Operating income$1.3B$1.4B$1.3B$1.5B
Net income$1.1B$4.2B$1.4B$1.5B
EPS (diluted)1.836.972.302.44
Operating cash flow$1.6B$542.3M$895.8M$1.2B
Cash$2.9B$3.0B$1.1B$769.0M
Long-term debt$598.3M$597.7M$597.0M$596.3M
Buybacks$893.4M$1.2B$879.6M$1.7B
SEC XBRL, fiscal years, as known on 2026-10-27

EW Stock Sonar score 6/7 axes

Find similar shapesCompare

EW ranks highest on financial health (85th percentile) and profitability (76th), and lowest on insider conviction (5th), among Medical Devices peers.

ProfitHealthGrowthInsidersInstitutionsRisk
Profitability
76
Inputs
  • Return on equity+9.5% · 78 pct, sector of 183
  • Return on assets+7.3% · 82 pct, sector of 214
  • Return on invested capital+12.4% · 60 pct, sector of 36
  • Return on capital employed+11.9% · 85 pct, sector of 188
Financial health
85
Inputs
  • Debt to equity0.06x · 75 pct, sector of 159
  • Cash flow to debt2.87x · 95 pct, sector of 150
Growth
53
Inputs
  • Revenue growth, YoY+11.5% · 53 pct, sector of 219
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
5
Inputs
  • Net Form 4 buying (codes P and S), 180d-$11.3M · 11 pct, sector of 140
  • Insider buyers, 180d0 · 0 pct, sector of 142
Institutional and government
65
Inputs
  • Funds adding, latest quarter646 · 97 pct, sector of 191
  • Congress net buyers, 365d-1 · 11 pct, universe of 719
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quarters$1.9M · 88 pct, sector of 50
Risk and compliance
39
Inputs
  • Short interest, % of float+1.7% · 75 pct, sector of 240
  • Recalls per $1B revenue, 3y2.31 per $1B · 27 pct, sector of 116
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-K+22.6% · 14 pct, sector of 198
1 not measured: US patents
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

EW filings, in plain words

Are Edwards Lifesciences insiders buying or selling EW?

In the 180 days to 2026-10-27, Edwards Lifesciences insiders were net sellers, a net $11.4M across purchases and sales reported on Form 4, by 7 sellers.

Have members of Congress traded EW?

Yes. In the year to 2026-10-27, 0 House members disclosed buying EW and 1 House member disclosed selling it; the latest on record is a sale by Josh Gottheimer dated 2025-11-19.

Are there planned insider sales of EW?

Yes. 7 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-27, covering $8.1M of stock; the latest, by Dahl Andrew M., was filed 2026-08-31.

Read the full summary

In the 180 days to 2026-10-27, Edwards Lifesciences insiders were net sellers of EW, a net $11.4M across purchases and sales reported on Form 4 by 7 sellers. 8% of the 26 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. In the year to 2026-10-27, 0 members of Congress disclosed buying EW and 1 member disclosed selling it; the latest on record is a sale by Josh Gottheimer dated 2025-11-19. Insiders filed 7 Form 144 notices of intent to sell in the 90 days to 2026-10-27, covering $8.1M of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies